FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington,	D.C.	2054

STATEMENT OF	CHANGES IN	BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

55 CAMBRIDGE PARKWAY, SUITE 800E

MA

(State)

1. Name and Address of Reporting Person\*

02142

(Zip)

**CAMBRIDGE** 

(City)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

Series   Therapeutics   Inc.   MCRB   Control   Contro						or S	ection 3	30(h) of	the Inv	/estr	ment	Company Act o	of 1940								
Cambool Stock	1. Name and Address of Reporting Person* <u>Flagship Ventures Fund IV General</u>										(Check all applicable)										
	Partner	LLC				_				_									Oth		ecify
Common Stock   11/23/2020   1/23/2020									ransa	ction	n (Mo	nth/Day/Year)				below	/)		belo	ow)	
A		,	,	,		11/2		.0													
Line   Common Stock   11/23/2020   Johnson	55 CAM	BRIDGE P	ARKWAY, SUL	TE 800	0E	4 If	Amend	ment D	ate of	Orig	ninal F	-iled (Month/Da	av/Year	,	6 In	ndividual or	Joint/G	roup Fili	na (Che	ck Anı	olicable
Campon Stock   11/23/2020   1	(Stroot)									Og	,a		.y, .ou.	′		e)			• .		
Table   - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   1. Title of Security (Instr. 3)   2. Transaction   Date		IDGE M	A 0	2142											2	Y Form	filed by				
Title of Security (Instr. 3)	(City)	(St								_											
Pate   Month/Day/Year)   Franchiculty   Franchicu			Table	I - No	on-Deriva	tive	Secu	rities	Acqu	ıire	d, D	isposed of	f, or E	3enefi	icial	lly Own	ed				
Code   V   Amount   (6) or   Price   Transaction(a)   Transaction(b)   T	1. Title of	Security (Ins	tr. 3)	[	Date	ear) i	xecution	tion Date,	Tra Co	Transaction Code (Instr.		Disposed Of (D) (Instr. 3, 4 an			Securities Beneficial Owned Fo	Securities Beneficially Owned Following		Direct Indirect	Indirect Beneficial Ownership		
11/23/2020									Cod	de	v	Amount	(A) or (D)	Price		Transaction				(insti	. 4)
Common Stock	Common	Stock			11/23/202	0			<b>J</b> (1	1)		3,587,820	D	\$0.0	00	4,434	,600	:	I		tnote <sup>(2)</sup>
11/23/2020   15/50   1,186,310   D   \$0.00   3,258,134   I   See Footnote(6)	Common	Stock			11/23/202	0			<b>J</b> (1	1)		642,180	D	\$0.0	00	1,283	,282		I		tnote <sup>(3)</sup>
Common Stock   11/23/2020   J(7)   1,481,481   D   \$0.00   2,962,963   I   See Footmote(9)	Common	Stock			11/23/202	0			<b>J</b> (1	1)		966,234	D	\$0.0	00	0			I		tnote <sup>(4)</sup>
Common Stock  11/23/2020  17/3  1,481,481  1 Solution Date (Instr. 4)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year)  Transaction Date (Instr. 3)  Transaction Date (Instr. 3)  Transaction Date (Instr. 3)  Transaction Date (Instr. 3)  Transaction Date (Instr. 4)  Transaction Date (Instr.	Common	Stock			11/23/202	0			J <sup>(5</sup>	5)		1,186,310	D	\$0.0	00	3,258	,134	:	I		tnote <sup>(6)</sup>
Common Stock  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible security (e.g., puts, calls, warrants, options, convertible securities)  L. Title of Derivative Securities Acquired (b.) or Date Security (Month/Day/Year)  [Instr. 3)  [Instr. 3, 4]  [Instr. 4]  [Ins	Common	Stock			11/23/202	0			J	7)		1,481,481	D	\$0.0	00	2,962	,963		I		tnote <sup>(8)</sup>
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  1. Title of Derivative Conversion (Month/Day/Year) Price of Derivative Security (Instr. 3) Price of Derivative Security (Month/Day/Year) Price of Derivative Security (Instr. 3) And Securities (A) or Disposed of (D) (Instr. 3, 4 and 5)  1. Name and Address of Reporting Person*  Flagship Ventures Fund IV General Partner  LLC  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  5. Number (6. Date Exercisable and Execution Date (Month/Day/Year) (Month/Da	Common	Stock			11/23/202	0			J <sup>(7</sup>	7)		43,154	D	\$0.0	00	0			I		tnote <sup>(9)</sup>
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  1. Title of Derivative Securities (Month/Day/Year)  1. Name and Address of Reporting Person*  Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, options, convertible securities)  3. Transaction Date (Privative Securities Underlying Derivative Securities Underlying Derivative Security (Instr. 5)  1. Title of Derivative Securities (Month/Day/Year)  2. Conversion or Exercise (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  4. Transaction Code (Instr. 4)  5. Number of Expiration Date (Month/Day/Year)  6. Date Exercisable and Expiration Date (Month/Day/Year)  8. Price of Derivative Securities Underlying Derivative Securities Und	Common	Stock														2,734	,994		I		tnote <sup>(10)</sup>
(e.g., puts, calls, warrants, options, convertible securities)  1. Title of Derivative Derivative Security (Instr. 3)  1. Title of Derivative Security Security Security Security Security Security Security Security Securities (A) or Disposed of (D) (Instr. 3, 4 and 5)  1. Name and Address of Reporting Person*  (e.g., puts, calls, warrants, options, convertible securities)  3. Transaction Date Execution Date, if any (Month/Day/Year) Securities (Month/Day/Year)  1. Name and Address of Reporting Person*  Flagship Ventures Fund IV General Partner  LLC	Common	Stock														376,0	018		I		tnote <sup>(11)</sup>
1. Title of Derivative Security (Instr. 3)  1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security (Instr. 3)  3. Transaction Date (Expiration Date (Month/Day/Year) (Month/Day/Year)  4. Stransaction Date (Month/Day/Year)  8. Price of Derivative Security (Instr. 5)  9. Number of Derivative Security (Instr. 5)  10. Ownership Form: Direct (D) Owner Ship Security (Instr. 4)  11. Nature of Indirect (Month/Day/Year)  12. Name and Address of Reporting Person*  Flagship Ventures Fund IV General Partner  LLC			Tal	ble II												y Owne	d	,			
Code V (A) (D) Date Exercisable Expiration Date Title Shares  1. Name and Address of Reporting Person*  Flagship Ventures Fund IV General Partner  LLC	Derivative Conversion or Exercise (Instr. 3) Price of Derivative		Execu if any	ecution Date, Tra		Insaction de (Instr. Securitie Acquirer (A) or Dispose of (D) (Instr. 3,		iber (itive ties ed	6. Da Expi	ate Ex	ercisable and Date	7. Titl Amou Secul Unde Deriv Secul	Amount of Securities Underlying Derivative Security (Insti		Derivative Security	derivati Securiti Benefic Owned Followi Reporte Transac	ive Owner ies Form: Direct or Ind (I) (Insection(s)		ship of Indirec Beneficia (D) Ownershi rect (Instr. 4)	of Indirect Beneficial Ownership	
Flagship Ventures Fund IV General Partner  LLC						Code	v	(A)					Title	or Number of	er						
				enera	al Partner																
			(First)	(N	Middle)		-														

(Last)	(First)	(Middle)
55 CAMBRIDGE	E PARKWAY, SU	JITE 800E
(Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
1. Name and Address <u>Flagship Ventu</u>		
(Last) 55 CAMBRIDGE	(First) E PARKWAY, SU	(Middle) JITE 800E
(Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
1. Name and Address Nutritional He LLC		on* <u>d General Partner</u>
(Last) 55 CAMBRIDGE	(First) E PARKWAY, SU	(Middle) JITE 800E
(Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
Nutritional He (Last) 55 CAMBRIDGE	(First)	(Middle)
(Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
1. Name and Address Flagship Pione		on*
(Last) 55 CAMBRIDGE	(First) E PARKWAY, SU	(Middle) JITE 800E
(Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
1. Name and Address Flagship Pione LLC		on* <u>/I General Partner</u>
(Last) 55 CAMBRIDGE	(First) E PARKWAY, SU	(Middle) JITE 800E
(Street) CAMBRIDGE	MA	02142

(Last)	(First)	(Middle)	
55 CAMBRIDGE	E PARKWAY,	SUITE 800E	
,			
(Street)			
CAMBRIDGE	MA	02142	
(City)	(State)	(Zip)	
Name and Address	s of Reporting Po	erson*	
AFEYAN NO			
(Last)	(First)	(Middle)	
55 CAMBRIDGE	E PARKWAY,	SUITE 800E	
(Street)			
CAMBRIDGE	MA	02142	
(City)	(State)	(Zip)	

## **Explanation of Responses:**

- 1. On November 23, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 3,587,820 shares and 642,180 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 837,782 shares and 128,452 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. received 335,171 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-19 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
- 2. Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering and as a manager of Flagship Fund IV GP.
- 3. Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- 4. Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- 5. On November 23, 2020, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") distributed to its limited partners, pro rata and without consideration, 1,186,310 shares of the Issuer's common stock. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
- 6. Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan Ph.D. is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- 7. On November 23, 2020, Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI") distributed to its limited partners and sole general partner, Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP"), pro rata and without consideration, 1,481,481 shares of the Issuer's common stock. Flagship Fund VI GP, in turn, distributed to its members, pro rata and without consideration, the 43,154 shares it received from Flagship Fund VI. Each of Noubar B. Afeyan, Ph.D. and a trust for the benefit of Dr. Afeyan's children received 12,853 shares through Flagship Fund VI GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
- 8. Shares held by Flagship Fund VI. Flagship Fund VI GP is the general partner of Flagship Fund VI. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan Ph.D. is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- 9. Shares held by Flagship Fund VI GP. Flagship Pioneering is the manager of Flagship Fund VI GP. Noubar B. Afeyan Ph.D. is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- 10. Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Each of the reporting persons except VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
- 11. Shares held by Noubar B. Afeyan, Ph.D. Each of the reporting persons except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Includes 12,853 shares held through a trust for the benefit of Dr. Afeyan's children. Dr. Afeyan disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares for Section 16 or any other purpose.

## Remarks:

General Partner LLC, By: /s/ 11/25/2020 Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: Manager Flagship Ventures Fund IV, L.P., By: Flagship Ventures Fund IV General Partner LLC, 11/25/2020 By: /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: Manager Flagship Ventures Fund IV-Rx, L.P., By: Flagship Ventures Fund IV General 11/25/2020 Partner LLC, By: /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: Manager Nutritional Health LTP Fund General Partner LLC, By: /s/ Noubar B. Afeyan, Name: 11/25/2020 Noubar B. Afeyan, Ph.D., Tit<u>le: Manager</u> Nutritional Health LTP Fund, L.P., By: Nutritional Health LTP Fund General Partner 11/25/2020 LLC, its general partner, By: <u>/s/ Noubar B. Afeyan, Name:</u> Noubar B. Afeyan, Ph.D., Title: Manager

Flagship Ventures Fund IV

Flagship Pioneering, Inc., By: 11/25/2020 /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: CEO, Sole Shareholder & Director Flagship Pioneering Fund VI General Partner LLC, By: Flagship Pioneering, Inc., its 11/25/2020 manager, By: /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: CEO, Sole Shareholder & Director Flagship Pioneering Fund VI, L.P., By: Flagship Pioneering Fund VI General Partner LLC, its general partner, By: Flagship Pioneering, Inc., its 11/25/2020 manager, By: /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: CEO, Sole Shareholder & Director Noubar B. Afeyan, Ph.D., by: 11/25/2020 /s/ Noubar B. Afeyan \*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.